Inflawell ® improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.

Sepideh Barzin TondLaurent BalenciNasim KhajaviradMohammadreza SalehiAbbas TafakhoriMohammad Reza ShahmohammadiFereshteh GhiasvandSirous JafariSara AbolghasemiFarzad MokhtariSomayyeh Mahmoodi BaramTayebe ZareiDavood KazemiEsmaeil MohammadnejadAkram Shah-HosseiniAlireza Haghbin ToutounchiSoudabeh FallahAli RiaziSaeed Karima

Published in: Inflammopharmacology (2022)

The trial has been registered in https://www.irct.ir with unique identifier: IRCT20170315033086N10 ( https://en.irct.ir/trial/51631 ). IRCT is a primary registry in the WHO registry network ( https://www.who.int/clinical-trials-registry-platform/network/primary-registries ).

Keyphrases

clinical trial
phase ii
double blind
phase iii
placebo controlled
study protocol
open label
sars cov
high throughput
randomized controlled trial
radiation therapy
rectal cancer